Clinical Trial Update: Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. [Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 2 immunotherapy combination with radiation for high-risk prostate cancer, evaluating N-803, ETBX-071, and M-CENK with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ETBX-071
• M-CENK
• N-803

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: High-risk Prostate Cancer | Phase 2 | Status: NOT_YET_RECRUITING